Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.

BMC Cancer · 2025 · PMC12306011 · PMID 40731270

Europe PMC DOI

hedged sentences

0.0572

closest p · 1.1× alpha

0.0608

boldest claim

The sentences

near-significantP = 0.0572so close (0.05 < p ≤ 0.1)

The change rate of granulocyte-macrophage colony-stimulating factor (GM-CSF) differed between the BJIKT and placebo groups, with a near-significant difference observed ( P = 0.0572).

also in 699 other papers

showed a trendP = 0.0608so close (0.05 < p ≤ 0.1)

The BJIKT group showed a trend towards an increase in CD3 + CD4 + T cells ( P = 0.0608), whereas no significant changes were observed in the placebo group ( P = 0.7513).

also in 16,965 other papers

a positive trendno p-value reported

Additionally, the FACIT-F (TOI-F) results showed a positive trend favoring the BJIKT treatment group compared to the placebo group.

also in 3,891 other papers

did not reach statistical significanceno p-value reported

Regarding PD-1 + CD4 + T cells, a decrease was observed in the BJIKT group ( P = 0.0742), though it did not reach statistical significance.

also in 33,519 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.